Compare Stocks: RPTX, RGNX, ALT, and YDES

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALT Altimmune	$2.32 +0.2%	$3.03	$2.29 ▼ $6.44	$450.31M	0.06	4.28 million shs	2.20 million shs
RGNX REGENXBIO	$6.99 +1.5%	$8.89	$5.45 ▼ $16.19	$461.10M	1.13	1.44 million shs	410,667 shs
RPTX Repare Therapeutics	$2.65 +0.8%	$2.62	$1.24 ▼ $2.66	$114.24M	0.97	516,093 shs	1.22 million shs
YDES YD Bio	$6.73 +5.9%	$4.51	$1.70 ▼ $22.00	$476.70M	-1.55	145,764 shs	29,309 shs

7 Best Space Stocks to Own in 2026

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALT Altimmune	-4.94%	-13.16%	-30.00%	-18.95%	-41.81%
RGNX REGENXBIO	-5.23%	-9.35%	-20.83%	-38.57%	-38.84%
RPTX Repare Therapeutics	0.00%	0.00%	0.00%	0.00%	+41.71%
YDES YD Bio	+4.26%	+8.16%	+66.06%	+158.54%	+635,999,900.00%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALT Altimmune	$2.32 +0.2%	$3.03	$2.29 ▼ $6.44	$450.31M	0.06	4.28 million shs	2.20 million shs
RGNX REGENXBIO	$6.99 +1.5%	$8.89	$5.45 ▼ $16.19	$461.10M	1.13	1.44 million shs	410,667 shs
RPTX Repare Therapeutics	$2.65 +0.8%	$2.62	$1.24 ▼ $2.66	$114.24M	0.97	516,093 shs	1.22 million shs
YDES YD Bio	$6.73 +5.9%	$4.51	$1.70 ▼ $22.00	$476.70M	-1.55	145,764 shs	29,309 shs

7 Best Space Stocks to Own in 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALT Altimmune	-4.94%	-13.16%	-30.00%	-18.95%	-41.81%
RGNX REGENXBIO	-5.23%	-9.35%	-20.83%	-38.57%	-38.84%
RPTX Repare Therapeutics	0.00%	0.00%	0.00%	0.00%	+41.71%
YDES YD Bio	+4.26%	+8.16%	+66.06%	+158.54%	+635,999,900.00%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALT Altimmune	2.70	Moderate Buy	$14.33	519.15% Upside
RGNX REGENXBIO	2.71	Moderate Buy	$23.17	231.66% Upside
RPTX Repare Therapeutics	2.00	Hold	$3.00	13.21% Upside
YDES YD Bio	1.00	Sell	N/A	N/A

Current Analyst Ratings Breakdown

Latest RPTX, RGNX, ALT, and YDES Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/5/2026	RGNX REGENXBIO	Mizuho Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Outperform	$22.00
10/5/2026	RGNX REGENXBIO	Mizuho Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Strong-Buy
9/28/2026	RGNX REGENXBIO	HC Wainwright Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy
9/23/2026	ALT Altimmune	Evercore Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Outperform
9/21/2026	ALT Altimmune	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (D-)
9/4/2026	RGNX REGENXBIO	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (E+)
8/25/2026	RGNX REGENXBIO	HC Wainwright Subscribe to MarketBeat All Access to unlock brokerage rankings	Lower Price Target	Buy	$23.00 ➝ $21.00
8/25/2026	RGNX REGENXBIO	Robert W. Baird Subscribe to MarketBeat All Access to unlock brokerage rankings	Lower Price Target	Outperform	$32.00 ➝ $29.00
8/12/2026	RGNX REGENXBIO	Zacks Research Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Strong Sell ➝ Hold
8/10/2026	RGNX REGENXBIO	HC Wainwright Subscribe to MarketBeat All Access to unlock brokerage rankings	Lower Price Target	Buy	$26.00 ➝ $23.00
8/7/2026	RGNX REGENXBIO	Morgan Stanley Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Overweight	$18.00

(Data available from 10/15/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALT Altimmune	$31K	14,526.10	N/A	N/A	$1.99 per share	1.16
RGNX REGENXBIO	$174.48M	2.64	N/A	N/A	$2.03 per share	3.44
RPTX Repare Therapeutics	$11.87M	9.62	N/A	N/A	$3.56 per share	0.74
YDES YD Bio	N/A	N/A	N/A	N/A	N/A	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALT Altimmune	-$88.09M	-$0.78	N/A	N/A	N/A	N/A	-31.41%	-26.96%	11/5/2026 (Estimated)
RGNX REGENXBIO	-$193.88M	-$3.79	N/A	N/A	N/A	-112.58%	-220.07%	-46.04%	11/5/2026 (Estimated)
RPTX Repare Therapeutics	-$84.69M	-$1.69	N/A	N/A	N/A	N/A	-60.15%	-52.24%	N/A
YDES YD Bio	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Latest RPTX, RGNX, ALT, and YDES Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/5/2026	Q3 2026	ALT Altimmune	-$0.14	N/A	N/A	N/A	$0.00 million	N/A
11/5/2026	Q3 2026	RGNX REGENXBIO	-$1.2367	N/A	N/A	N/A	$14.88 million	N/A
9/1/2026	Q2 2026	YDES YD Bio	N/A	$0.05	N/A	$0.0450	N/A	$0.42 million
8/12/2026	Q2 2026	ALT Altimmune	-$0.1355	-$0.12	+$0.0155	-$0.12	$0.00 million	N/A
8/6/2026	Q2 2026	RGNX REGENXBIO	$0.0787	$0.43	+$0.3513	$0.43	$97.63 million	$108.02 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALT Altimmune	N/A	N/A	N/A	N/A	N/A
RGNX REGENXBIO	N/A	N/A	N/A	N/A	N/A
RPTX Repare Therapeutics	N/A	N/A	N/A	N/A	N/A
YDES YD Bio	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALT Altimmune	0.07	26.78	26.78
RGNX REGENXBIO	N/A	2.86	2.86
RPTX Repare Therapeutics	N/A	10.71	10.71
YDES YD Bio	N/A	N/A	N/A

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALT Altimmune	78.05%
RGNX REGENXBIO	88.08%
RPTX Repare Therapeutics	85.09%
YDES YD Bio	N/A

Insider Ownership

Company	Insider Ownership
ALT Altimmune	1.60%
RGNX REGENXBIO	14.22%
RPTX Repare Therapeutics	11.50%
YDES YD Bio	N/A

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALT Altimmune	57	194.52 million	191.41 million	Optionable
RGNX REGENXBIO	371	66.01 million	56.63 million	Optionable
RPTX Repare Therapeutics	180	43.11 million	38.15 million	Optionable
YDES YD Bio	15	70.79 million	N/A	N/A

RPTX, RGNX, ALT, and YDES Headlines

Recent News About These Companies

YD Bio Limited (NASDAQ:YDES) Shares Shorted: Short Interest Up 312.8% in September

October 11, 2026 | americanbankingnews.com

YD Bio and EG BioMed Launch AI-Based 10-Cancer Risk Factor Assessment

October 6, 2026 | globenewswire.com

Cours YD Bio Limited

September 24, 2026 | zonebourse.comZ

YD Bio (NASDAQ:YDES) CEO Ethan Phd Shen Purchases 3,100 Shares of Stock

September 11, 2026 | insidertrades.com

中概股跌幅榜前十，YD Bio Limited(YDES.US)跌22.71%，房多多(DUO.US)跌20.85%

September 1, 2026 | finet.hkF

YD Bio Ltd (YDES)

September 1, 2026 | finance.yahoo.com

YD Bio Files First-Half 2026 Results, Reports Improved Equity Position

September 1, 2026 | tipranks.com

YD Bio Limited Reports First-Half 2026 Financial Results, 315% Revenue Growth and Net Income of $6.7 Million

August 31, 2026 | quiverquant.comQ

YD Bio Limited Reports Unaudited Financial Results for the Six Months Ended June 30, 2026

August 31, 2026 | globenewswire.com

YDES - YD Bio Limited

August 26, 2026 | seekingalpha.com

Yd Bio Limited publie un article de revue évalué par les pairs dans Nutrients et lance deux produits nutraceutiques à Taïwan

August 26, 2026 | zonebourse.comZ

YD Bio Announces Peer-Reviewed Publication in Nutrients, Co-Authored with Physicians from the Taiwan Chronic Disease Healthcare Association and the Future Health Institute

August 25, 2026 | globenewswire.com

YD Bio Launches a Physician-Partnership Initiative in Taiwan with the Announcement of Two Nutraceutical Products in Collaboration with the Taiwan Chronic Disease Healthcare ...

August 11, 2026 | markets.businessinsider.com

YD Bio Launches Physician-Led Nutraceuticals in Taiwan to Build Consumer Health Ecosystem

August 11, 2026 | tipranks.com

YD Bio Highlights Peer-Reviewed Publication on New Computational Framework for Keratoconus Research

August 4, 2026 | markets.businessinsider.com

YD Bio Launches Cross-Border Cancer Testing Pilot with Numia Health to Evaluate Expanded Access to Molecular Diagnostics in Canada

July 28, 2026 | finance.yahoo.com

YD Bio and EG BioMed Conclude Successful Exhibition at BIO Asia-Taiwan 2026, Highlighting Innovations in Ophthalmology, Oncology Diagnostics, and Clinical Services

July 24, 2026 | markets.businessinsider.com

YD Bio Limited

July 15, 2026 | cnn.com

YD Bio Limited Ordinary Shares (YDES) Insider Activity

July 14, 2026 | nasdaq.com

YD Bio Expands U.S. Laboratory Footprint to 46 States, Strengthening DNA-Methylation Early Cancer Detection Operations

July 2, 2026 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

RPTX, RGNX, ALT, and YDES Company Descriptions

Altimmune NASDAQ:ALT

$2.32 +0.01 (+0.22%)

As of 01:32 PM Eastern

Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.

REGENXBIO NASDAQ:RGNX

$6.98 +0.11 (+1.53%)

As of 01:31 PM Eastern

REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy. It also develops RGX-121 for the treatment of mucopolysaccharidosis type II that is in Phase III clinical trial; RGX-111 for treating mucopolysaccharidosis type I; RGX-181 for the treatment of late infantile neuronal ceroid lipofuscinosis type II; and RGX-381 to treat the ocular manifestations of CLN2 disease. In addition, the company licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies. Further, it has a collaboration and license agreement with AbbVie Global Enterprises Ltd. to develop ABBV-RGX-314 outside the United States. REGENXBIO Inc. was incorporated in 2008 and is headquartered in Rockville, Maryland.

Repare Therapeutics NASDAQ:RPTX

Repare Therapeutics Inc., a clinical-stage precision oncology company, engages in the discovery and development of therapeutics by using its synthetic lethality approach in Canada and the United States. It uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform, to discover, validate, and build a pipeline of SL-based therapeutics that focuses on genomic instability, including DNA damage repair. The company's lead product candidate is Camonsertib (RP-3500), an oral small molecule inhibitor under Phase ½ development for the treatment of solid tumors with specific DNA damage repair-related genomic alterations. It is also developing Lunresertib (RP-6306), a PKMYT1 Inhibitor, which is under Phase 1 clinical trial for tumors with genetic alterations characterized by CCNE1 amplification; RP-1664, an oral PLK4 inhibitor, under Phase 1 clinical trial designed to harness the synthetic lethal relationship with TRIM37 amplification or overexpression in solid tumors; and RP-3467, a polymerase theta adenosinetriphosphatase (ATPase) inhibitor, a SL target associated with BRCA mutations and other genomic alterations. The company has license and collaboration agreement with Hoffmann-La Roche Inc. and F. Hoffmann-La Roche Ltd; Bristol-Myers Squibb Company; New York University; and Ono Pharmaceutical Co., as well as a clinical study and collaboration agreement with Debiopharm to explore the synthetic lethal combination of PKMYT1 and WEE1 inhibition in cancer. Repare Therapeutics Inc. was incorporated in 2016 and is headquartered in Montréal, Canada.

YD Bio NASDAQ:YDES

$6.73 +0.37 (+5.88%)

As of 01:31 PM Eastern

YD Bio Limited is a biotechnology company advancing DNA methylation-based cancer detection technology and ophthalmologic innovations.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest RPTX, RGNX, ALT, and YDES Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest RPTX, RGNX, ALT, and YDES Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

RPTX, RGNX, ALT, and YDES Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

RPTX, RGNX, ALT, and YDES Company Descriptions

Altimmune NASDAQ:ALT

REGENXBIO NASDAQ:RGNX

Repare Therapeutics NASDAQ:RPTX

YD Bio NASDAQ:YDES

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest RPTX, RGNX, ALT, and YDES Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest RPTX, RGNX, ALT, and YDES Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

RPTX, RGNX, ALT, and YDES Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

RPTX, RGNX, ALT, and YDES Company Descriptions

Altimmune NASDAQ:ALT

REGENXBIO NASDAQ:RGNX

Repare Therapeutics NASDAQ:RPTX

YD Bio NASDAQ:YDES

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools